ImClone Systems to Present at the NASDAQ 12th Investor Program - London
NEW YORK, May 11, 2004 (BUSINESS WIRE) -- ImClone Systems Incorporated (NASDAQ:
IMCL) announced today that Daniel S. Lynch, Chief Executive Officer, is
scheduled to present at the Life Sciences Forum during the NASDAQ 12th Investor
Program in London on Wednesday, May 12, 2004, from 2:00 - 2:30 PM British Summer
Time (9:00 - 9:30 AM Eastern Time). Mr. Lynch will provide a corporate overview,
including comments on the Company's product portfolio.
The presentation will be webcast live and may be accessed by visiting ImClone
Systems' website at www.imclone.com. A replay of the webcast will also be
available immediately after the conclusion of the presentation. Investors can
access the webcast under "Presentations" in the "Investor Relations" section of
ImClone Systems' website.
About ImClone Systems Incorporated
ImClone Systems Incorporated is committed to advancing oncology care by
developing and commercializing a portfolio of targeted biologic treatments
designed to address the medical needs of patients with a variety of cancers. The
Company's three programs include growth factor blockers, angiogenesis inhibitors
and cancer vaccines. ImClone Systems' strategy is to become a fully integrated
biopharmaceutical company, taking its development programs from the research
stage to the market. ImClone Systems' headquarters and research operations are
located in New York City, with additional administration and manufacturing
facilities in Branchburg, New Jersey.
Certain matters discussed in this news release may constitute forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of
1995 and the Federal securities laws. Although the company believes that the
expectations reflected in such forward-looking statements are based upon
reasonable assumptions it can give no assurance that its expectations will be
achieved. Forward-looking information is subject to certain risks, trends and
uncertainties that could cause actual results to differ materially from those
projected. Many of these factors are beyond the company's ability to control or
predict. Important factors that may cause actual results to differ materially
and could impact the company and the statements contained in this news release
can be found in the company's filings with the Securities and Exchange
Commission including quarterly reports on Form 10-Q, current reports on Form 8-K
and annual reports on Form 10-K. For forward-looking statements in this news
release, the company claims the protection of the safe harbor for
forward-looking statements contained in the Private Securities Litigation Reform
Act of 1995. The company assumes no obligation to update or supplement any
forward-looking statements whether as a result of new information, future events
or otherwise.
SOURCE: ImClone Systems Incorporated
CONTACT: ImClone Systems Incorporated
Investors:
Andrea F. Rabney, 646/638-5058
or
Stefania Bethlen, 646/638-5058
Customize your Business Wire news & multimedia to match your needs.
Get breaking news from companies and organizations worldwide.
Logon for FREE today at www.BusinessWire.com.
Copyright (C) 2004 Business Wire. All rights reserved.
KEYWORD: NEW YORK UNITED KINGDOM INTERNATIONAL EUROPE
INDUSTRY KEYWORD: PHARMACEUTICAL
CONFERENCE
CALLS
|
1
|
